Products and approval Fingolimod is commercially available in capsule form (Gilenya) and has been approved in many countries since 2011. First generic products were registered in 2020 and entered the market in 2021. Fingolimod was the first specific multiple sclerosis drug to be administered orally, rather than being injected subcutaneously or as an infusion. In … Fingolimod
Products Siponimod was approved in film-coated tablet form in the United States in 2019 and in many countries in 2020 (Mayzent). Structure and properties Siponimod (C29H35F3N2O3, Mr = 516.6 g/mol) is present in the drug as a 2:1 co-crystal with the fumaric acid and as a white powder. The drug was developed starting from fingolimod, … Siponimod
Products Ozanimod was approved in the United States and many countries in 2020 in hard capsule form (Zeposia). Structure and properties Ozanimod (C23H24N4O3, Mr = 404.5 g/mol) is present in the drug as ozanimod hydrochloride, a white solid that is highly soluble in water. Active metabolites are involved in the effects. Effects Ozanimod (ATC L04AA38) … Ozanimod